Subscribe Now Subscribe Today
Research Article

Repossession of Brain Complications in a Streptozotocin Induced Diabetic Rat by Exogenous Melatonin Administration

Younis Ahmad Hajam, Seema Rai, Ankita Roy, Muddasir Basheer and Hindole Ghosh
Facebook Twitter Digg Reddit Linkedin StumbleUpon E-mail

Background and Objective: Diabetes is one of the foremost culprit responsible in degrading the health of a person in this stressful life. The present study focused on protective effect of melatonin (MEL) on brain of streptozotocin (STZ) induced diabetic rat. Materials and Methods: Thirty six male rats were randomly divided into six groups, each group contain six rats, Control, STZ induced, STZ+Mel, Mel, STZ+GB (Glibenclamide) and GB. Streptozotocin was injected for six days continuously thereafter blood glucose level were censored after 72 h. The animals showing blood glucose level above 250 mg dL–1 were considered as diabetic and were administered with exogenous Mel for 4 weeks. Animals were euthanized after 4 weeks. Brain of all respective groups were dissected, weighed and fixed in Bouin’s fixative for histological studies as well as processed for the assessment of biochemical variables viz lipid peroxidation (LPO), antioxidative defense system; reduced glutathione (GSH), superoxide dismutase (SOD) and catalase (CAT) activity and total protein quantification. Data were analyzed by students t-test followed by one-way ANOVA to compare between different experimental groups. Results: Streptozotocin (STZ)-induced diabetic rats exhibited significant increase in rate of LPO (p<0.001) but a significant decrease in organ weight, GSH, SOD, CAT and total protein content (p<0.05, 0.01 and 0.001). However, melatonin treatment restored LPO, weight of brain, total protein, catalase (CAT) SOD, GSH (p<0.05, 0.01 and 0.001). Decrement in hippocampal volume signifies the brain cell damaged might have resulted due to increased free radical load during diabetes. Further, histophotomicrographs of diabetic rats showed decrease in astrocyte number indicating compromised state of immune defense system. Melatonin administration however revived the brain architecture because of its antiapoptotic and antioxidant nature. Conclusion: Therefore, melatonin might be suggested as neuroprotective therapeutic molecule regulating morphological, anatomical and biochemical functions of brain during diabetes induced brain impairments.

Related Articles in ASCI
Similar Articles in this Journal
Search in Google Scholar
View Citation
Report Citation

  How to cite this article:

Younis Ahmad Hajam, Seema Rai, Ankita Roy, Muddasir Basheer and Hindole Ghosh, 2017. Repossession of Brain Complications in a Streptozotocin Induced Diabetic Rat by Exogenous Melatonin Administration. International Journal of Zoological Research, 13: 64-73.

DOI: 10.3923/ijzr.2017.64.73



Diabetes is a multi-faceted metabolic syndrome1, it is one of the major health concerns in the public across the globe2. Approximately 220 million people are expected to be suffer from diabetes mostly Low and Middle Income Countries (LMIC)3. In 2008, diabetes has costed about 1.256 million deaths globally in LMIC4. The high level of blood sugar is one of the major risk factor for atherosclerosis, inflammatory disease of the arterial walls, due to the formation of fatty streaks and plaques. Atherosclerosis can lead to stroke or heart attack. Diabetes also affects the angiogenesis and wound healing5. It also hinders the supply of vitamin-C to both retina and brain which in turn results in the Blood-Brain Barrier (BBB) `permeability1. WHO reported that diabetes is the 8th leading cause of death and is mainly characterised by high rates of mortality and morbidity6. Diabetes occurs either because of lack of insulin or because of the presence of factors that oppose the action of insulin7. Symptoms of diabetes include frequent urination, increased thirst and increased hunger, as it provokes to numerous dysfunctions.

Brain is the central organ of the nervous system and it lies within the cranial cavity of the skull. It maintains the homeostasis by receiving sensory inputs, integrating the information and helps in making decisions8. Motor activities and behavioural postures are controlled by the brain9,10. Cells of the brain include neurons and astrocytes that maintain the BBB. Hyperglycaemic end products contribute to the pathologic substrate for Alzheimer’s disease and other neurodegenerative diseases. It also leads to stress and depression3. Prolonged diabetes results in the decreased volume of white and gray matter11 and also leads to the decreased number of astrocytes which might be down regulating the immune cells of the brain. Persistent diabetic episodes also lead to increase in hippocampal volumes12. Due to diabetes, number of astrocytes are altered disturbing the BBB which causes many neurodegenerative diseases by weakening the immune system of the brain.

Melatonin is the main secretory product of pineal gland and is known as pineal neurohormone13. It is a peptide hormone belonging to the indole compound14. Melatonin has pleiotropic functions as immune modulator15, antioxidant and anti-apoptotic mediator16. It is also involved in bone metabolism17. Melatonin signal is also critical for glucose regulation in blood and in maintaining homeostasis18. Along with these, clinical investigation of melatonin therapy in elderly patients has demonstrated a relaxation effect19 and the improvement of depressed mood and memory20. It has positive impact on angiogenesis and wound healing and is effective in improving sleep disturbances resulting from Alzheimer’s diseases21.

Image for - Repossession of Brain Complications in a Streptozotocin Induced Diabetic Rat by Exogenous Melatonin Administration
Fig. 1: Proposed neuroprotective role of exogenous melatonin

Melatonin restores the oxidative stress in different organs like liver, kidney and ovaries22,23.

Streptozotocin is a permanent diabetogenic inducing drug and is synthesized by a soil microbe, Streptomyces achromogenes (a Gram-positive bacterium) having extensive spectrum of antibacterial properties. Due to selective toxicity to the beta cells of the pancreatic cells24, it causes the DNA damage which induces the activation of poly ADP-ribosylation which leads to diabetes induction25.

Therefore, present study was conducted to reveal biochemical followed by histologically alterations resulted during diabetic condition and further to evaluate protective role of melatonin to overcome diabetes induced brain complications.

Diagrammatic representation of STZ induced oxidative stress and free radical generated nervous damages and the hypothesized protective role of melatonin (Fig. 1).


Animal model and maintenance: Male albino rats (Rattus norvegicus) weighing approximately 180±10 g of same age group were procured from Defence Research and Development Establishment (DRDE) Gwalior, M.P. and kept under standard laboratory conditions (25±2°C temperature, 60-70% humidity and 12 h photoperiod). The experimental study was carried out during the month of January-March, 2017 at Department of Zoology, Guru Ghasidas Vishwavidyalaya, Bilaspur (C.G), India. Rats were fed with pellet diets and water ad libitum. All experimental procedures for care and use of laboratory animals were approved by the Institutional Animal Ethics Committee (IAEC), Guru Ghasidas Vishwavidyalaya, Bilaspur (C.G), India (Registration Number: 994/Go/ERe/S/06/CPCSEA). After two weeks of acclimatization, the rats were divided into following six different groups.

Experimental design:

Group I: Normal control rats (0.1M Sodium Citrate buffer)
Group II: Diabetic control (STZ 15 mg kg–1 b.wt., 6 days, i.p.)
Group III: STZ+MEL [STZ 15 mg kg–1 (6 days) + 1 mg kg–1 b. wt., 4 weeks i.p.]
Group IV: MEL (1mg kg–1 b.wt., 4 weeks)
Group V: STZ+GB (STZ 15 mg kg–1+0.5 mg kg–1 b.wt., 4 weeks, p.o.)
Group VI: GB (0.5 mg kg–1 b.wt., 4 weeks)

The STZ dissolved in 0.1 M citrate buffer of pH 7.4 was administered intraperitoneally for consecutively 6 days. Blood glucose level of the animals was monitored using glucometer (ACCU CHECK) after 72 h of streptozotocin treatment. Rats with blood glucose level higher than 250 mg dL–1 up to 6th day were considered as diabetic model. After successful induction, MEL and GB were given for 4 weeks. At the end of 30th day, animals of each group were sacrificed following complete anaesthesia. Tissues were dissected out, cleaned and were fixed in Bouin’s fixative and also stored at -20°C for the study of different parameters.

Chemicals required: BHT, Copper Sulphate, DNTB (0.01 M), Folin’s Solution, Glacial Acetic Acid, Glibenclamide, H2O2, Melatonin, Methanol, NaOH (0.2 N), NADH, NBT, PBS Phosphate Buffer (50 mM), Phosphoric Acid, PMS, Sodium Carbonate, Sodium Potassium Tartrate, Sodium Pyrophosphate buffer (pH-7.0), Streptozotocin, Sucrose Buffer, TBA (0.6%), TCA (10%), Tris Buffer (0.2 M, pH-8.2), Tris-HCL Buffer (pH-7.4). All the chemicals and reagents used to carry out biochemical and histological analysis were of analytical grade.

Parameters studied
Morphological and gravimetric analysis: Brain of each group was carefully separated from cranium. They were weighed using the weighing balance and then photography was done with the help of camera (OLYMPUS CX2181ED) to compare with the different experimental groups.

Lipid Peroxidation Assay (LPO): Lipid peroxidation assay was conducted according to Ohkawa et al.26. The homogenate was prepared by Tris-HCl buffer (pH 7.4). Equal amounts of homogenate and BHT were taken and 3 mL of phosphoric acid and 1 mL of TBA was mixed to it. After the centrifugation at 3500 rpm pellet was decanted and only supernatant was taken. The absorbance was measured at 535 nm.

Glutathione Reduced Assay (GSH): GSH assay was performed according to Sedlak and Lindsay27. The 100 mg of fresh tissue was homogenised in 1 mL of sucrose buffer. To 100 μL of homogenate 1.5 mL of Tris Buffer (pH-8.2) was added and the volume was made up to 10 mL by methanol. After centrifugation at 3000 rpm for 15 min absorbance was measured at 412 nm.

Assay of Superoxide Dismutase (SOD): SOD was conducted following the method of Kakkar et al.28. The homogenate was prepared in Phosphate Buffer Saline. 0.2 mL of homogenate was centrifuged at 1500 rpm for 10 min and only the supernatant was taken. Then 1.2 mL of sodium pyrophosphate buffer, 0.1 mL of PMS and 0.3 mL of NBT were added to the supernatant and finally absorbance was taken at 560 nm.

Catalase Assay (CAT): The assay was performed according to Beer and Sizer29. The homogenate was prepared in phosphate buffer. Phosphate buffer (ph 8.2) with volume of 2.5 mL was added to 0.1 mL of homogenate and centrifuged at 3000 rpm for 15 min. Forty microliter of the supernatant was taken and 3 mL of H2O2 phosphate buffer to it. The absorbance was taken at 240 nm.

Protein estimation: The total protein content was quantified following the method of Lowry et al.30 with some modifications. Two hundred microliter (200 μL) of 10% TCA was added to the homogenate and centrifuged at 2000 rpm for 15 min. To the pellet 1 mL of NAOH (0.2 N) was added. From the above prepared sample 0.1 mL was pipette out, to this 0.4 mL of distilled water was added. Five milliliter of Solution C was added then added and then incubated for 10 min. Five hundred microliter (500 μL) of Folin’s solution was added to develop color and absorbance was taken at 625 nm.

Histological studies: Tissues were fixed in Bouin’s fixative for 24 h. They were processed through the various steps of dehydration and clearance and then embedded in paraffin wax. Tissue sections of 5 μm thick were cut using rotary microtome (Leica RM 2125RT5). Hematoxylin eosin stained slides were observed under light microscope for histopathological changes.

Statistical analysis: Results were expressed as Mean±SE. Data were analyzed by student’s t-test followed by one-way ANOVA using IBM 20.0 version software31. Results were considered significant at different levels (p<0.05, 0.01 and 0.001).


Morphological differences: Brain showed some well demarcated changes in hippocampal area. In diabetic rats the hippocampal region of the brain was shrinked and size decreases, while as melatonin treated diabetic rats showed significant restoration in the hippocampal area (Fig. 2).

Effect of melatonin on gravimetric analysis: Diabetic rats showed significant decrease in body weight (p<0.01), whereas melatonin co-administration to the diabetic rats increases the body weight (p<0.05) (Fig. 3).

Effect of melatonin on lipid peroxidation: The free radical production was noted significantly higher (p<0.001) in brain of streptozotocin (STZ) induced diabetic rats. Administration of melatonin showed significant decrease (p<0.05) in LPO level of brain in streptozotocin (STZ) induced diabetic rats (Fig. 4).

Effect of melatonin on reduced glutathione GSH): The GSH level was noted decreased significantly in brain of streptozotocin (STZ) diabetic rats (p<0.001). Melatonin supplemented to streptozotocin diabetic rats showed significant increase (p<0.05) in GSH level (Fig. 5).

Effect of melatonin on superoxide dismutase (SOD) activity: A significant decrease in SOD activity was observed in streptozotocin (STZ) induced diabetic rats in brain (p<0.001), whereas melatonin administration to the diabetic rats showed improvement in antioxidant enzyme levels (p<0.05) (Fig. 6).

Effect of melatonin on catalase activity: Streptozotocin (STZ) induced diabetic rats revealed significantly decreased catalase (CAT) activity (p<0.01) (enzyme which cleaves the H2O2 into water and molecular oxygen) in brain. Melatonin treatment to streptozotocin (STZ) induced diabetic model showed significant increase in catalase activity (p<0.01) (Fig. 7).

Image for - Repossession of Brain Complications in a Streptozotocin Induced Diabetic Rat by Exogenous Melatonin Administration
Fig. 2(a-f):
Showing morphological changes in the hippocampal region of the brain in different experimental groups, (a) Con-(Control) group no change in size of hippocampus, (b) STZ (Streptozotocin) group the hippocampal area decreased in size (c) STZ +Mel (Streptozotocin+melatonin) group recovery in size of hippocampus, (d) STZ+GB (Streptozotocin+Glibenclamide) group showed recovery in the hippocampical region and (e-f) Mel and GB treated groups does not showed any change in the hippocampus

Image for - Repossession of Brain Complications in a Streptozotocin Induced Diabetic Rat by Exogenous Melatonin Administration
Fig. 3: Effect of melatonin on weight of brain
Histogram represents Mean±SE, N = 6, aa: p<0.01; CON vs. STZ, b: p<0.05; STZ vs. STZ+MEL, cc: p<0.01; STZ vs. MEL, d: p<0.05: STZ vs. STZ+GB, e: p<0.05: STZ vs. GB

Image for - Repossession of Brain Complications in a Streptozotocin Induced Diabetic Rat by Exogenous Melatonin Administration
Fig. 4:Effect of melatonin on lipid peroxidation of brain
Histogram represents Mean±SE, N = 6, aaa: p<0.01: CON vs. STZ, b: p<0.05: STZ vs. STZ+MEL, c: p<0.05: STZ vs. MEL, d: p<0.05: STZ vs. STZ+GB, e = p<0.05: STZ vs. GB

Image for - Repossession of Brain Complications in a Streptozotocin Induced Diabetic Rat by Exogenous Melatonin Administration
Fig. 5:Effect of melatonin on GSH level of brain
Histogram represents Mean±SE, N = 6, aaa: p<0.001: CON vs. STZ, b: p<0.05: STZ vs. STZ+MEL, cc: p<0.01: STZ vs. MEL, d: p<0.05: STZ vs. STZ+GB, e: p<0.05: STZ vs. GB

Effect of melatonin on total protein estimation: The protein content was noted significantly decreased in brain of streptozotocin (STZ) induced diabetic rats (p<0.05). Administration of melatonin significantly restored the total protein contents of brain in streptozotocin (STZ) induced diabetic rats (p<0.05) (Fig. 8).

Image for - Repossession of Brain Complications in a Streptozotocin Induced Diabetic Rat by Exogenous Melatonin Administration
Fig. 6:
Effect of melatonin on Superoxide dismutase (SOD) activity of brain
Histogram represents Mean±SE, N = 6, aaa: p<0.001: CON vs. STZ, b: p<0.05: STZ vs. STZ+MEL, cc: p<0.01: STZ vs. MEL, d: p<0.05: STZ vs. STZ+GB, e: p<0.05: STZ vs. GB

Image for - Repossession of Brain Complications in a Streptozotocin Induced Diabetic Rat by Exogenous Melatonin Administration
Fig. 7:Effect of melatonin on catalase (CAT) activity of brain
Histogram represents Mean±SE, N = 6, aa: p<0.01: CON vs. STZ, bb: p<0.01: STZ vs. STZ+MEL, cc: p<0.01: STZ vs. MEL, d: p<0.05: STZ vs. STZ+GB, ee: p<0.01: STZ vs. GB

Image for - Repossession of Brain Complications in a Streptozotocin Induced Diabetic Rat by Exogenous Melatonin Administration
Fig. 8:Effect of melatonin on protein contents of brain
Histogram represents Mean±SE, N = 6, a: p<0.05: CON vs. STZ, b: p<0.05: STZ vs. STZ+MEL, c: p<0.01: STZ vs. MEL, d: p<0.05: STZ vs. STZ+GB, e: p<0.05: STZ vs. GB

Effect of melatonin on histological architecture of brain: Brain of STZ induced diabetic rats showed decrease in astrocyte number indicating compromised state of immune defence system. Melatonin administration however, revived the brain architecture as compared to control group and therefore, may be said as immune regulator of brain/CNS via immune modulation (Fig. 9).

Image for - Repossession of Brain Complications in a Streptozotocin Induced Diabetic Rat by Exogenous Melatonin Administration
Fig. 9(a-l):
Photomicrographs of rat brain sections in different experimental groups stained with Hematoxylin and Eosin (10X and 40X), (a-b) Histopathological sections of pancreas in control rat revealed normal astrocyte and glial cells, (c-d) Rat treated with MEL (per se) showing normal cellular structure with abundant astrocytes and glial cells, (e-f) GB (per se), hypoglycaemic drug, (g-h) STZ induced diabetic control rats revealed decreased astrocyte number and brain alterations, (i-j) Brain of rats treated with MEL (1 mg kg–1) after induction of diabetes showed restoration in glial and astrocyte number and (k-l) STZ+GB, brain of rats treated with hypoglycaemic drug (glibenclamide) after successful induction of diabetes to compare with melatonin treated diabetic rats


Prolonged diabetes lead to an increased risk of acquiring vascular dementia, hemodynamic impairments (Stroke), Cognitive deficits, behavioral modulations, damages in the Blood Brain Barrier (BBB) and other neurodegenerative diseases. It is a condition in which the ultimate response of the insulin is decreased than normal31. This might be because of improper functioning of either the cells that produce insulin or by the cells that have to respond to the insulin32. In humans, the diabetogenic process appears to be caused by immune destruction of the β- cells; part of this process is apparently mediated by white blood cell production of active oxygen species33. Diabetes can be characterized by a state of chronic hyperglycemia (peripheral insulin resistance), glucosuria, polyurea, polydipsia (excessive thirst), polyphagia (constant hunger), sudden weight loss, ketoacidosis and ketonuria (urinary ketones)34,35 nephropathy, cardiovascular diseases etc.

Diabetes is the most common serious metabolic disorder36, where a bunch of functional and morphological alterations can occur in the central nervous system37. These changes include abnormal expression of hypothalamic neuropeptides, astrogliosis in the hippocampus38, decreased synaptic plasticity in the hippocampus, neurotoxicity and changes in glutamate neurotransmission39. Several evidences have shown that diabetes may be associated with learning and memory deficits in humans40. Studies examining the effects of STZ-induced diabetes on memory function in mice and rat models have also shown deficits in memory retention and retrieval, compared to non-diabetic animal models41. Astrocytes have effective roles in supporting the neurons, maintenance of the Blood Brain Barrier (BBB)42, vascular reactivity, regulation of extracellular glutamate levels, energy metabolism and protection from reactive oxygen species in the central nervous system43. In the present study the astrocytes were found to be decreased in STZ-induced diabetic rats which might have disturbed the neurons and physiology of the brain. These astrocytes regulates immune functions of the neuron, decrement in the astrocytes weakens the immune system of the brain. Altered astrocyte activity contributes to the CNS pathophysiology in diabetes in different parts of the brain which affect coordination and working efficiency of the diabetic patients. Results of current study coincide with the previous studies which indicated that diabetes led to astroglial alterations by decreasing the number of astrocytes. Melatonin administration to the diabetic rats restored the number of astrocytes, as melatonin is known as immune modulator44. These results were confirmed by administering melatonin to normal rats which does not showed any alteration in astrocyte count. Both high and low dose of melatonin protects the astrocytes45.

In the present study, weight of brain was found to be decreased in the STZ-induced diabetic rats. It has been reported that depression and stress caused by diabetic conditions are the two factors which decreases the weight of brain46 type-1 and type-2 diabetes causes depression in patient, which might be the reason that diabetes leads to weight loss47. Melatonin might have reduced the stress and depression that may be a possible hypothetical protective role of melatonin to restore the weight of brain in the STZ-induced diabetic rats towards control group. The STZ-induced diabetic rats exhibited shorter hippocampus region in the brain morphological observations documented in the photomicrographs. The hippocampus is the region of brain where high receptors for insulin are found suggesting that it plays a major role in memory. The administration of MEL increases the hippocampus area towards normal because the antioxidants (i.e., melatonin) restores the cell damage and causes cell proliferation in the hippocampus region of brain48 as shown in the Fig. 2.

Hyperglycemia is the main reason for significant damage to the body through the accumulation of metabolic toxins such as superoxides and Advanced Glycation End Products (AGEPs), causing ischaemia, hypoxia, oxidative stress and inflammation. It also can also cause apoptosis of neurons and gliosis, which might be lead to cognitive impairment and even central nervous system disorders such as Alzheimer’s Disease (AD)49. Multiple genes or proteins play important roles in diabetic neuropathy. Oxidative stress is a process during which balance between free radical generation and antioxidant defence gets disturbed. These free radicals damage the cells of any organ system. Lipid peroxidation is widely used procedure to measure the oxidative stress in blood, serum or any other organ50. Oxidative stress is associated with several indices of adiposity and a low antioxidant defence51. In present study rate of lipid peroxidation level was found to be higher in the STZ-induced diabetic rats, our result was supported by previous findings of Vincent et al.52. It has well documented that melatonin is an antioxidant that can easily cross cell membranes and the BBB53. It directly as well as indirectly act as an antioxidant to scavenge Reactive Oxygen Species (ROS) and Reactive Nitrogen Species (RNS) including H2O2, OH‾, O2‾ and NO‾ 54. The MEL normalised the LPO level by activating the antioxidant enzymes as the MEL functions as to enhance the potential antioxidant enzymatic systems. Because of these mutilated defensive antioxidant properties, melatonin might have reduced the lipid peroxidation in STZ-induced diabetic rat. The findings of this study were confirmed by administration of melatonin and standard hypoglycaemic drug glibenclamide to the other groups of rats which does not showed any abnormal change in free radical production.

Diabetes is associated with decreased cellular glutathione concentrations55. Oxidative stress and ROS formation are markedly increased by uncontrolled hyperglycaemia56. Streptozotocin causes reduction and weakening in the antioxidative defence like glutathione reduced (GSH) as was observed in STZ injected group of rats. While scavenging property of MEL might be responsible in the treatment of increased glutathione formation in STZ-induced diabetic rat, this increment in the GSH level in the tissue might be due to the donation of electron by the indole ring of melatonin. The results were supported by the alone treatment of melatonin and glibenclamide to separate group of animals which showed regulatory roles to maintain the glutathione levels in the tissues.

The free radicals generated during the different glucose metabolizing pathways following STZ induction of diabetes might have been scavenged by melatonin. Because of its high potential of antioxidative property, as free radical scavenger which in turn led to enhanced and up regulation of the antioxidative enzymes (GSH, SOD and CAT)22. Thus, simultaneously down regulating the free radical production. Therefore, melatonin may be a potent agent in reducing the oxidative damage caused by Streptozotocin in diabetic patients. In the present study the SOD and catalase activity was found to be decreased in STZ-induced diabetic conditions which is similar to previous findings of Cojocaru57. Melatonin restored antioxidative enzyme level as that of antidiabetic molecule glibenclamide treated group of rats22. It is proposed that MEL suppresses the degradation of the nuclear factor-E2-related factor (Nrf2) and increases its nuclear translocation via its interacting with ubiquitin ligase in the nucleus and then Nrf2 stimulates the transcription of antioxidant enzymes (e.g., MnSOD and catalase) through binding to the antioxidant response element58. This property of MEL might have been the reason that catalase activity was increased in administration of MEL in STZ-induced diabetic rat.

During the diabetic condition the proteins mostly becomes glycosylated and non-functional. The oxidative stress causes the disintegration of plasma membrane, leading to leakage of intracellular proteins and other enzymes into blood plasma. The protein level was found to be decreased in STZ-induced diabetic conditions. The MEL might have been beneficial in the view related to protein contents that protein content was found to be increased in administration of MEL in streptozotocin-induced diabetic rats. These finding could be because of MEL, which influences the insulin secretion and homeostasis59 and its oral administration exert anti- hyperglycemic effect in young rats as insulin sensitizer and by improvement in β-cell function60. Clinical results indicate that MEL improves glycemic control in blood59.


It is concluded that melatonin is a powerful antioxidant molecule. It can be used as a neuroprotective either as supplement/adjuvant therapeutic molecule to improve various deficits associated with diabetic neuropathy. Thus, it might provides a useful therapeutic option in humans to reduce oxidative stress and the associated neuronal damages in diabetic patients.


Finding of present study discovers the antagonising effect of exogenous administration of melatonin against the neurodegeneration and damages in the rat brain during STZ induced diabetic condition. Melatonin normalized the oxidative stress and reversed the brain damage by renormalizing of antioxidant system. Therefore, antioxidants might be the promising therapeutic approach in reducing diabetes induced neuronal damages and its related complications. Therapeutic properties of melatonin may help making independent melatonin based drug discovery process in future. However such novel therapy may be further explored to un turn various pharmacokinetic in order to implement in medical science.


Authors are highly grateful to the Department of Zoology, Guru Ghasidas Vishwavidyalaya (Central University) for providing available research facilities. Authors are also thankful to Dr. SK Verma (Department of Zoology, GGV) for lending his help during microscopy.

1:  Prasad, S., R.K. Sajja, P. Naik and L. Cucullo, 2014. Diabetes mellitus and blood-brain barrier dysfunction: An overview. J. Pharmacovigilance, Vol. 2. 10.4172/2329-6887.1000125

2:  Richard, I.G.H. and A.H. Neil, 2012. Essential Endocrinology and Diabetes. 6th Edn., Wiley-Blackwell Publication, West Sussex, pp: 233-240.

3:  WHO. and WONC., 2008. Integrating Mental Health into Primary Care: A Global Perspective. World Health Organization, World Organization of National Colleges, Academies and Academic, Geneva, London.

4:  Kaur, G., G.H. Tee, S. Ariaratnam, A.S. Krishnapillai and K. China, 2013. Depression, anxiety and stress symptoms among diabetics in Malaysia: A cross sectional study in an urban primary care setting. BMC Family Pract., Vol. 14. 10.1186/1471-2296-14-69

5:  Soybir, G., C. Topuzlu, O. Odabas, K. Dolay, A. Bilir and F. Koksoy, 2003. The effects of melatonin on angiogenesis and wound healing. Surg. Today, 33: 896-901.
CrossRef  |  Direct Link  |  

6:  Zimmet, P., K.G.M.M. Alberti and J. Shaw, 2001. Global and societal implications of the diabetes epidemic. Nature, 414: 782-787.
CrossRef  |  Direct Link  |  

7:  Watkins, P.J., 2003. ABC of Diabetes. 5th Edn., BMJ Publishing Group, London, pp: 1-13.

8:  Marth, E., 2010. A Dictionary of Science. 6th Edn., Oxford University Press, Oxford, pp: 109-110.

9:  Tortora, G.J. and B. Derrickson, 2012. The Cardiovascular System: Blood Vessels and Hemodynamics. In: Principles of Anatomy and Physiology, Tortora, G.J. and B. Derrickson (Eds.)., Wiley, USA., pp: 610-635.

10:  Stockley, C., C. Oxlade and J. Werthein, 1999. The Usborne Illustrated Dictionary of Science. Usborne Pub. Ltd., London, pp: 302-309.

11:  Bryan, R.N., M. Bilello, C. Davatzikos, R.M. Lazar and A. Murray et al., 2014. Effect of diabetes on brain structure: The action to control cardiovascular risk in diabetes MR imaging baseline data. Radiology, 272: 210-216.
Direct Link  |  

12:  Hershey, T., D.C. Perantie, J. Wu, P.M. Weaver, K.J. Black and N.H. White, 2010. Hippocampal volumes in youth with type 1 diabetes. Diabetes, 59: 236-241.
CrossRef  |  Direct Link  |  

13:  Peters, J.L., V.M. Cassone and M.J. Zoran, 2005. Melatonin modulates intercellular communication among cultured chick astrocytes. Brain Res., 1031: 10-19.
CrossRef  |  Direct Link  |  

14:  Lin, G.J., S.H. Huang, S.J. Chen, C.H. Wang, D.M. Chang and H.K. Sytwu, 2013. Modulation by melatonin of the pathogenesis of inflammatory autoimmune diseases. Int. J. Mol. Sci., 14: 11742-11766.
CrossRef  |  Direct Link  |  

15:  Carrillo-Vico, A., P.J. Lardone, N. Alvarez-Sanchez, A. Rodriguez-Rodriguez and J.M. Guerrero, 2013. Melatonin: Buffering the immune system. Int. J. Mol. Sci., 14: 8638-8683.
CrossRef  |  Direct Link  |  

16:  Galano, A., D.X. Tan and R.J. Reiter, 2013. On the free radical scavenging activities of melatonin's metabolites, AFMK and AMK. J. Pineal Res., 5: 245-257.
CrossRef  |  Direct Link  |  

17:  Suzuki, N., M. Somei, A. Seki, R.J. Reiter and A. Hattori, 2008. Novel bromomelatonin derivatives as potentially effective drugs to treat bone diseases. J. Pineal Res., 45: 229-234.
CrossRef  |  Direct Link  |  

18:  Claustrat, B., J. Brun and G. Chazot, 2005. The basic physiology and pathophysiology of melatonin. Sleep Med. Rev., 9: 11-24.
CrossRef  |  Direct Link  |  

19:  Zhdanova, I.V., R.J. Wurtman, M.M. Regan, J.A. Taylor, J.P. Shi and O.U. Leclair, 2001. Melatonin treatment for age-related insomnia. J. Clin. Endocrinol. Metab., 86: 4727-4730.
CrossRef  |  Direct Link  |  

20:  Jean‐Louis, G., H. Gizycki and F. Zizi, 1998. Melatonin effects on sleep, mood and cognition in elderly with mild cognitive impairment. J. Pineal Res., 25: 177-183.
CrossRef  |  Direct Link  |  

21:  Cheng, Y., Z. Feng, Q.Z. Zhang and J.T. Zhang, 2006. Beneficial effects of melatonin in experimental models of Alzheimer disease. Acta Pharmacol. Sinica, 27: 129-139.
CrossRef  |  Direct Link  |  

22:  Rai, S., Y.A. Hajam, M. Basheer and H. Ghosh, 2016. Biochemical and histopathological inflections in hepato-renal tissues of streptozotocin (STZ) induced diabetic male rats: Impact of exogenous melatonin administration. J. Clin. Res. Bioeth., Vol. 7. 10.4172/2155-9627.1000290

23:  Rai, S., M. Basheer, H. Ghosh, D. Acharya and Y.A. Hajam, 2015. Melatonin attenuates free radical load and reverses histologic architect and hormone profile alteration in female rat: An in vivo study of pathogenesis of letrozole induced poly cystic ovary. J. Clin. Cell. Immunol., Vol. 6. 10.4172/2155-9899.1000384

24:  Mansford, K.R.L. and L. Opie, 1968. Comparison of metabolic abnormalities in diabetes mellitus induced by streptozotocin or by alloxan. Lancet, 291: 670-671.
CrossRef  |  Direct Link  |  

25:  Szkudelski, T., 2001. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol. Res., 50: 537-546.
PubMed  |  Direct Link  |  

26:  Ohkawa, H., N. Ohishi and K. Yagi, 1979. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem., 95: 351-358.
CrossRef  |  PubMed  |  Direct Link  |  

27:  Sedlak, J. and R.H. Lindsay, 1968. Estimation of total, protein-bound and nonprotein sulfhydryl groups in tissue with Ellman's reagent. Anal. Biochem., 25: 192-205.
CrossRef  |  PubMed  |  Direct Link  |  

28:  Kakkar, P., B. Das and P.N. Viswanathan, 1984. A modified spectrophotometric assay of superoxide dismutase. Indian J. Biochem. Biophys., 21: 130-132.
PubMed  |  Direct Link  |  

29:  Beers, Jr. R.F. and I.W. Sizer, 1952. A spectrophotometric method for measuring the breakdown of hydrogen peroxide by catalase. J. Biol. Chem., 195: 133-140.
PubMed  |  Direct Link  |  

30:  Lowry, O.H., N.J. Rosebrough, A.L. Farr and R.J. Randall, 1951. Protein measurement with the folin phenol reagent. J. Biol. Chem., 193: 265-275.
PubMed  |  Direct Link  |  

31:  Snedecor, G.W.,W.G. Cochran and C. Ames, 1989. Statistical Method. 8th Edn., Affiliated East-West Press, Iowa State, pp: 217–236.

32:  Bliss, M., 1993. The history of insulin. Diabetes Care, 16: 4-7.
CrossRef  |  Direct Link  |  

33:  WHO., 2013. Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy. World Health Organization, Geneva, pp: 63.

34:  Oberley, L.W., 1988. Free radicals and diabetes. Free Radical Biol. Med., 5: 113-124.
CrossRef  |  Direct Link  |  

35:  Joslin, E.P. and F.H. Lahey, 1928. Diabetes and hyperthyroidism. Am. J. Med. Sci., 176: 1-22.

36:  Kessler, R.C., K.A. McGonagle, S. Zhao, C.B. Nelson and M. Hughes et al., 1994. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch. Gen. Psychiatry, 51: 8-19.
PubMed  |  Direct Link  |  

37:  Gispen, W.H. and G.J. Biessels, 2000. Cognition and synaptic plasticity in diabetes mellitus. Trends Neurosci., 23: 542-549.
PubMed  |  Direct Link  |  

38:  Biessels, G.J., S. Staekenborg, E. Brunner, C. Brayne and P. Scheltens, 2006. Risk of dementia in diabetes mellitus: A systematic review. Lancet Neurol., 5: 64-74.
CrossRef  |  PubMed  |  Direct Link  |  

39:  Saravia, F.E., J. Beauquis, Y. Revsin, F. Homo-Delarche, E.R. de Kloet and A.F. de Nicola, 2006. Hippocampal neuropathology of diabetes mellitus is relieved by estrogen treatment. Cell Mol. Neurobiol., 26: 941-955.
CrossRef  |  Direct Link  |  

40:  Revsin, Y., F. Saravia, P. Roig, A. Lima, E.R. de Kloet, F. Homo-Delarche and A.F. de Nicola, 2005. Neuronal and astroglial alterations in the hippocampus of a mouse model for type 1 diabetes. Brain Res., 1038: 22-31.
CrossRef  |  PubMed  |  Direct Link  |  

41:  Liang, X.C., S.S. Guo and H. Nobuyoshi, 2006. Current status of clinical and experimental researches on cognitive impairment in diabetes. J. Chin. Integr. Med., 12: 68-74.
CrossRef  |  Direct Link  |  

42:  Biessels, G.J. and W.H. Gispen, 2005. The impact of diabetes on cognition: What can be learned from rodent models? Neurobiol. Aging, 26: 36-41.
CrossRef  |  PubMed  |  Direct Link  |  

43:  Afsari, Z.H., W.M. Renno and E. Abd‐El‐Basset, 2008. Alteration of glial fibrillary acidic proteins immunoreactivity in astrocytes of the spinal cord diabetic rats. Anat. Rec., 291: 390-399.
CrossRef  |  PubMed  |  Direct Link  |  

44:  Zonta, M., M.C. Angulo, S. Gobbo, B. Rosengarten, K.A. Hossmann, T. Pozzan and G. Carmignoto, 2003. Neuron-to-astrocyte signaling is central to the dynamic control of brain microcirculation. Nat. Neurosci., 6: 43-50.
CrossRef  |  PubMed  |  Direct Link  |  

45:  Rai, S., C. Haldar and R. Singh, 2009. Modulation of immunity in young-adult and aged squirrel, Funambulus pennanti by melatonin and p-chlorophenylalanine. Immun. Ageing, Vol. 6. 10.1186/1742-4933-6-5

46:  Martin, V., R.M. Sainz, I. Antolin, J.C. Mayo, F. Herrera and C. Rodriguez, 2002. Several antioxidant pathways are involved in astrocyte protection by melatonin. J. Pineal Res., 33: 204-212.
Direct Link  |  

47:  Delahanty, L.M., M. Peyrot, P.J. Shrader, D.A. Williamson, J.B. Meigs and D.M. Nathan, 2013. Pretreatment, psychological and behavioral predictors of weight outcomes among lifestyle intervention participants in the Diabetes Prevention Program (DPP). Diabetes Care, 36: 34-40.
CrossRef  |  Direct Link  |  

48:  Trief, P.M., D. Cibula, L.M. Delahanty and R.S. Weinstock, 2014. Depression, stress and weight loss in individuals with metabolic syndrome in SHINE, a DPP translation study. Obesity, 22: 2532-2538.
CrossRef  |  Direct Link  |  

49:  Kim, S.J., T.G. Son, H.R. Park, M. Park and M.S. Kim et al., 2008. Curcumin stimulates proliferation of embryonic neural progenitor cells and neurogenesis in the adult hippocampus. J. Biol. Chem., 283: 14497-14505.
CrossRef  |  Direct Link  |  

50:  Booya, F., F. Bandarian, B. Larijani, M. Pajouhi, M. Nooraei and J. Lotfi, 2005. Potential risk factors for diabetic neuropathy: A case control study. BMC Neurol., 10.1186/1471-2377-5-24

51:  Halliwell, B. and S. Chirico, 1993. Lipid peroxidation: Its mechanism, measurement and significance. Am. J. Clin. Nutr., 57: 715S-724S.
Direct Link  |  

52:  Vincent, H.K., K.E. Innes and K.R. Vincent, 2007. Oxidative stress and potential interventions to reduce oxidative stress in overweight and obesity. Diabetes Obesity Metab., 9: 813-839.
CrossRef  |  Direct Link  |  

53:  De Souza Bastos, A., D.T. Graves, A.P. de Melo Loureiro, C. Rossa Junior and S.C.T. Corbi et al., 2016. Diabetes and increased lipid peroxidation are associated with systemic inflammation even in well-controlled patients. J. Diabetes Complications, 30: 1593-1599.
CrossRef  |  PubMed  |  

54:  Reiter, R.J., D.X. Tan and L. Fuentes-Broto, 2010. Melatonin: A multitasking molecule. Progr. Brain Res., 181: 127-151.
CrossRef  |  Direct Link  |  

55:  Poeggeler, B., S. Thuermann., A. Dose, M. Schoenke, S.Burkhardt and R. Hardeland, 2002. Melatonin's unique radical scavenging properties-roles of its functional substituents as revealed by a comparison with its structural analogs. J. Pineal. Res., 33: 20-30.
CrossRef  |  PubMed  |  Direct Link  |  

56:  Whiting, P.H., A. Kalansooriya, I. Holbrook, F. Haddad and P.E. Jennings, 2008. The relationship between chronic glycaemic control and oxidative stress in type 2 diabetes mellitus. Br. J. Biomed Sci., 65: 71-74.
PubMed  |  Direct Link  |  

57:  Menon, V., M. Ram, J. Dorn, D. Armstrong and P. Muti et al., 2004. Oxidative stress and glucose levels in a population-based sample. Diabetes Res., 21: 1346-1352.
CrossRef  |  PubMed  |  Direct Link  |  

58:  Cojocaru, I.M., M. Cojocaru, C. Musuroi, M. Botezat, L. Lazar and A. Druta, 2003. Lipid peroxidation and catalase in diabetes mellitus with and without ischemic stroke. Rom. J. Internal Med., 42: 423-429.
PubMed  |  Direct Link  |  

59:  Vriend, J. and R.J. Reiter, 2015. The keap1-nrf2-antioxidant response element pathway: A review of its regulation by melatonin and the proteasome. Mol. Cell. Endocrinol., 401: 213-220.
CrossRef  |  PubMed  |  Direct Link  |  

60:  Sharma, S., H. Singh, N. Ahmad, P. Mishra and A. Tiwari, 2015. The role of melatonin in diabetes: Therapeutic implications. Arch. Endocrinol. Metab., 59: 391-399.
CrossRef  |  PubMed  |  Direct Link  |  

©  2021 Science Alert. All Rights Reserved